The association between hematological parameters and metabolic syndrome in Iranian men: A single center large-scale study

BACKGROUND Chronic obstructive pulmonary disease (COPD) is a global public health problem, and continuous monitoring is essential for both its management as well as the management of other chronic diseases. Telemonitoring using mobile health (mHealth) devices has the potential to promote self-management, improve control, increase quality of life, and prevent hospital admissions. OBJECTIVE This study aims to demonstrate whether a large-scale study assessing the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. This will allow our team to select the appropriate design and characteristics for our large-scale study. METHODS A total of 3 cohorts, with 9 participants in each, will use mHealth devices for 90 days while undergoing the current standard of care. These groups are: 9 “non-COPD,” otherwise healthy, smokers; 9 “grey zone” smokers (forced expiratory volume in 1 second/ forced vital capacity ≥0.70 after bronchodilator treatment; COPD Assessment Test ≥10); and 9 smokers diagnosed with Stage 1-3 COPD. Rates of recruitment, retention, and adherence will be measured. Overall, two mHealth devices will be utilized in the study: the AnaMed Original Equipment Manufacturer device (measures distance, energy expenditure, heart rate, and heart rate variability) and the Air Next mobile spirometry device. The mHealth devices will be compared against industry standards. Additionally, a questionnaire will be administered to assess the participants’ perceptions of the mHealth technologies used. RESULTS The inclusion of participants started in June 2019. Study results will be published in peer-reviewed scientific journals. CONCLUSIONS This study will demonstrate whether a large-scale study to assess the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. It will also allow the research team to select the appropriate design and characteristics for the large-scale study. CLINICALTRIAL ClinicalTrials.gov NCT04081961; https://clinicaltrials.gov/ct2/show/NCT04081961 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/16461

Download Full-text

Platelet-to-lymphocyte ratio as a novel marker of in-hospital and long-term adverse outcomes among patients with acute pulmonary embolism: A single center large-scale study

Thrombosis Research ◽

10.1016/j.thromres.2016.12.006 ◽

2017 ◽

Vol 150 ◽

pp. 33-40 ◽

Cited By ~ 9

Author(s):

Elif Hande Ozcan Cetin ◽

Mehmet Serkan Cetin ◽

Ugur Canpolat ◽

Ahmet Akdi ◽

Dursun Aras ◽

...

Keyword(s):

Pulmonary Embolism ◽

Large Scale ◽

Acute Pulmonary Embolism ◽

Adverse Outcomes ◽

Single Center ◽

Platelet To Lymphocyte Ratio ◽

Lymphocyte Ratio ◽

Large Scale Study

Download Full-text

FIRST LARGE-SCALE STUDY LINKS METABOLIC SYNDROME TO COGNITIVE IMPAIRMENT

Neurology Today ◽

10.1097/00132985-200503000-00005 ◽

2005 ◽

Vol 5 (3) ◽

pp. 8

Author(s):

Jo Stratmoen

Keyword(s):

Metabolic Syndrome ◽

Cognitive Impairment ◽

Large Scale ◽

Large Scale Study

Download Full-text

Evaluating Mobile Apps and Biosensing Devices to Monitor Physical Activity and Respiratory Function in Smokers With and Without Respiratory Symptoms or Chronic Obstructive Pulmonary Disease: Protocol for a Proof-of-Concept, Open-Label, Feasibility Study

JMIR Research Protocols ◽

10.2196/16461 ◽

2020 ◽

Vol 9 (3) ◽

pp. e16461 ◽

Cited By ~ 1

Author(s):

Almaz Sharman ◽

Baurzhan Zhussupov ◽

Dana Sharman ◽

Irina Kim

Keyword(s):

Chronic Obstructive Pulmonary Disease ◽

Metabolic Syndrome ◽

Heart Rate ◽

Pulmonary Disease ◽

Chronic Diseases ◽

Large Scale ◽

Chronic Obstructive ◽

Obstructive Pulmonary Disease ◽

Treatment Assessment ◽

Large Scale Study

Background Chronic obstructive pulmonary disease (COPD) is a global public health problem, and continuous monitoring is essential for both its management as well as the management of other chronic diseases. Telemonitoring using mobile health (mHealth) devices has the potential to promote self-management, improve control, increase quality of life, and prevent hospital admissions. Objective This study aims to demonstrate whether a large-scale study assessing the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. This will allow our team to select the appropriate design and characteristics for our large-scale study. Methods A total of 3 cohorts, with 9 participants in each, will use mHealth devices for 90 days while undergoing the current standard of care. These groups are: 9 “non-COPD,” otherwise healthy, smokers; 9 “grey zone” smokers (forced expiratory volume in 1 second/ forced vital capacity ≥0.70 after bronchodilator treatment; COPD Assessment Test ≥10); and 9 smokers diagnosed with Stage 1-3 COPD. Rates of recruitment, retention, and adherence will be measured. Overall, two mHealth devices will be utilized in the study: the AnaMed Original Equipment Manufacturer device (measures distance, energy expenditure, heart rate, and heart rate variability) and the Air Next mobile spirometry device. The mHealth devices will be compared against industry standards. Additionally, a questionnaire will be administered to assess the participants’ perceptions of the mHealth technologies used. Results The inclusion of participants started in June 2019. Study results will be published in peer-reviewed scientific journals. Conclusions This study will demonstrate whether a large-scale study to assess the use of mHealth devices to improve the treatment, assessment, compliance, and outcomes of chronic diseases, particularly COPD and cardio-metabolic syndrome, is feasible. It will also allow the research team to select the appropriate design and characteristics for the large-scale study. Trial Registration ClinicalTrials.gov NCT04081961; https://clinicaltrials.gov/ct2/show/NCT04081961 International Registered Report Identifier (IRRID) DERR1-10.2196/16461

Download Full-text